Related Experiment Video

Updated: Aug 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Anticoagulation: new challenges, old drugs

Brian Olshansky1

  • 1Department of Internal Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 4426A JCP, Iowa City, IA 52242, USA. brian-olshansky@uiowa.edu

Current Cardiology Reports
|August 18, 2005
PubMed

Insights

Warfarin anticoagulation effectively prevents stroke in atrial fibrillation (AF) patients but is difficult to manage. Ximelagatran shows similar stroke prevention efficacy with potentially fewer complications.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Atrial fibrillation (AF) management necessitates rate control, rhythm maintenance, and anticoagulation to prevent thromboemboli.
  • Warfarin is effective for stroke prevention in high-risk AF patients but presents challenges in management.
  • Ideal anticoagulants offer fewer interactions, uniform dosing, no routine monitoring, and reduced bleeding risk.

Purpose of the Study:

  • To compare the efficacy and safety of fixed-dose ximelagatran with warfarin in AF patients.
  • To evaluate ximelagatran as a potential alternative to warfarin for stroke prevention.

Main Methods:

  • Two large randomized noninferiority trials were conducted.
  • Patients with AF at high risk for stroke were included.
  • Fixed-dose ximelagatran was compared against warfarin therapy.

Main Results:

  • Ximelagatran demonstrated noninferiority to warfarin in preventing stroke and thromboembolic events.
  • The intention-to-treat analysis indicated comparable efficacy between the two anticoagulants.
  • Long-term risk profiles suggested similar or potentially improved safety with ximelagatran.

Conclusions:

  • Ximelagatran is as effective as warfarin in preventing stroke and thromboembolic events in AF patients.
  • Ximelagatran may offer a favorable risk profile compared to warfarin.
  • The findings support ximelagatran as a viable alternative for anticoagulation in AF management.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...